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Abstract
Purpose: Asthma exacerbations are a leading cause of hospital and emergency department admissions at pediatric institutions. The
objective of this study was to determine if patients who obtain discharge medications from a pediatric institution’s outpatient
pharmacy after an admission for asthma have a lower thirty-day readmission rate than those who do not obtain discharge
medications from the outpatient pharmacy. Methods: This multi-phase retrospective study included an initial chart review, an
intervention period, and a second chart review of the intervention period. The chart reviews included patients ages two years and
older with a discharge diagnosis of asthma or wheezing. During the intervention phase, pharmacists promoted use of the outpatient
pharmacy by patients admitted for these conditions using multiple methods. In each chart review, the patients readmitted for
asthma or wheezing within thirty days were classified as either outpatient pharmacy users (OPP users) or non-OPP users. Differences
in readmission rates between OPP users and non-OPP users, as well as differences in overall OPP utilization, were analyzed before
and during the intervention phase using a Chi-square test. Results: The initial chart review found no significant difference in thirty
2
day readmission rates between OPP users and non-OPP users (6.2% and 7.5%, respectively; χ = 1.15; p = 0.274). The number of OPP
2
users increased significantly from the first chart review to the second (11.8% and 45.9%, respectively; χ = 929.04, p < 0.001). The
second chart review revealed that OPP users had a significantly lower readmission rate than non-OPP users during the intervention
2
phase (2.3% and 10.9%, respectively; χ = 52.5; p < 0.001). Conclusion: Obtaining discharge medications from the OPP was associated
with a lower thirty-day readmission rate in children with asthma. Promoting use of the OPP for transitional care should continue to
be part of future efforts to decrease hospital readmissions.

Background
In recent years, researchers have identified the need for
health care providers and public health officials to improve
clinical outcomes in pediatric asthma by addressing gaps in
access to care, seizing opportunities for improvements in the
health care system, and examining asthma-related
1-3
hospitalizations. Inpatient (IP) hospitalizations are one
potential result of an exacerbation of asthma, which is a
chronic inflammatory condition of the airways. Exacerbations
also may lead to missed days of school and work for the child
and parent, impaired daily functions and quality of life,
1,4-6
emergency department (ED) visits, or death.
According to
the National Health Interview Survey, the prevalence of
asthma in children less than 18 years old has increased from
8.7% to 9.6% from 2001 to 2009, and is significantly higher
3
than in adults. The goal of treating asthma is to prevent
morbidity, which is measured by exacerbations and
7
progressive deterioration of lung function, and mortality.
Children who are ethnic minorities, under age five, from low-

income households, inner-city residents, or who are exposed
to tobacco smoke or air pollution have a higher risk of
1,4,7
experiencing morbidity and mortality from asthma.
Other
known risk factors for morbidity and mortality from asthma
include individuals with an increased frequency and severity
of past asthma exacerbations, multiple ED visits or IP
hospitalizations for asthma in the past year, or any history of
intubation or intensive care unit (ICU) admission for
7,8
asthma.
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The guidelines recommend continued treatment with several
7
prescription medications after an exacerbation, but children
diagnosed with asthma may have increased barriers to health
1,10-13
care, including unmet prescription needs.
Kogan and
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The National Heart, Lung, and Blood Institute (NHLBI) and the
National Asthma Education and Prevention Program (NAEPP)
Expert Panel Report 3 clinical guidelines released in 2007
emphasize the importance of preventative anti-inflammatory
treatment. Yet, asthma exacerbations continue to be a
3,4,7
leading cause of pediatric hospitalizations.
In 2007, there
were 41.4 hospitalizations and 132.7 ED visits for asthma per
9
10,000 children under age five. The Healthy People 2020
goal is to significantly reduce these numbers to 18.1
hospitalizations and 95.5 ED visits per 10,000 children.
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colleagues (2010) found that children in fair or poor health or
with special health care needs due to a chronic condition
(including use of prescription medications) were more likely
to be underinsured and experience barriers to appropriate
10
health care. Prescription access for asthmatics is crucial,
because poor adherence to therapy has been found to be a
14-18
prevalent cause of uncontrolled asthma.
Delays in
obtaining medication could lead to non-adherence,
13,16
uncontrolled asthma, and readmissions.
Pharmacists can play a pivotal role in the prevention of
19
morbidity and mortality due to asthma. Education and
management of asthmatics by pharmacists has been shown
to improve inhaler technique and medication adherence,
leading to better asthma control and reduced ED and IP
20-24
admissions.
Yet, these efforts are not effective unless the
patient has immediate access to prescription medications. As
discussed, high-risk asthmatic children, such as those recently
admitted for an exacerbation, may encounter several barriers
to obtaining prescription medications. An outpatient
pharmacy on the hospital campus may be able to eliminate
some of these barriers by dispensing discharge medications
to patients before they leave the campus, resulting in better
initial medication adherence and therefore a lower rate of
readmission within thirty days, which is equivalent to the
usual supply of medication dispensed. Therefore, the primary
objective of this study was to determine if patients who
obtain first-fill medications from a pediatric institution’s
outpatient pharmacy after an ED or IP admission for asthma
have a lower thirty-day readmission rate than patients who
do not obtain discharge medications from the outpatient
pharmacy. The secondary objectives of this study were to
examine the relationship between selected patient
characteristics (age, insurance, and type of readmission) and
OPP utilization for patients readmitted within 30 days.
Methods
This multiphase, interventional study was conducted at a
free-standing, tertiary pediatric institution with an on-campus
outpatient pharmacy. The institution has more than 350
inpatient beds and treated over 19,000 inpatients and 76,000
emergency department patients in 2010. The study included
three components: a pre-intervention retrospective chart
review, an intervention, and a second retrospective chart
review. The timeline (see Figure 1) details several important
stages of the study. The hospital Institutional Review Board
(IRB) gave the pre-intervention phase of the study expedited
approval. The intervention and second chart review were
considered quality improvement and were exempt from IRB
review.
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Pre-Intervention Retrospective Chart Review
The purpose of the initial chart review was to determine if
patients who obtained discharge medications from the
outpatient pharmacy (OPP) had a lower rate of thirty-day
readmissions than those who did not obtain discharge
medications from the OPP. Using the institution’s electronic
medical record (EMR), patients ages two and older admitted
to the hospital or ED with a principal ICD-9 diagnosis of
asthma or wheezing from October 2008 through June 2010
were identified. Each patient’s chart was analyzed for thirtyday readmission encounters, which were defined as an IP or
ED readmission within thirty-days of a prior IP or ED
admission. The OPP records of patients with thirty-day
readmission encounters were examined to determine
whether or not each readmitted patient had used the OPP to
fill his or her asthma medications within one day of discharge.
Readmitted patients then were classified into two groups:
OPP users or non-OPP users. Finally, the rates of thirty-day
readmission were calculated for each group and compared.
Intervention
The intervention was designed to increase the percent of
asthma patients utilizing the OPP upon discharge. Outpatient
pharmacists performed educational interventions with
patients’ families and clinical staff to encourage utilization of
the OPP. This effort, called Don’t Leave Without Them, was
part of a hospital-wide initiative to decrease asthma
admissions and took place from July 2010 to February 2011.
Monday through Friday, pediatric inpatients being treated for
asthma exacerbations were identified by outpatient
pharmacists via a consult order that was sent through the
EMR. The pharmacists visited each patient and their family
members at least once during their admission to educate the
family about the OPP and distribute a promotional card
detailing the services offered by the OPP, as well as its
location and hours of operation. Questions from the
patient/family were common, and often led to informal
discussions about medications, but no formal medication or
disease state education was performed. Occasionally, the
pharmacists were unable to make contact with a patient or
family during their admission. If the family chose to use the
OPP, the card acted as a reminder to their nurse to ensure
prescriptions were sent accordingly. In the ED, flyers
promoting the OPP were distributed to patients upon
admission by registration staff. These flyers served the same
purpose as the cards given to inpatients, but were not
complemented by a personal visit from a pharmacist.
Collaboration with nurses, respiratory therapists, medical
staff, discharge coordinators, and other hospital staff was
essential for the success of this program. Interventions
aimed at educating staff about the purpose of Don’t Leave
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Without Them were continuous and focused on the units that
treated the majority of asthma exacerbations, due to the
large number of clinical staff. The outpatient pharmacists
were in regular communication with the clinical leaders of
these units and worked with them to distribute weekly
updates on the program’s progress to their clinical staff.
Although the program was driven by two outpatient
pharmacists, several non-pharmacy clinicians and staff were
champions for the program, including discharge coordinators
who regularly called the outpatient pharmacists to let them
know which patients were going home that day, physicians,
nurse leaders, and administrators.
Second Retrospective Chart Review
Thirty day readmission rates were reassessed to determine
the impact of the intervention phase using a retrospective
chart review with the same inclusion criteria and methods as
the initial chart review, but for the time frame of the
intervention phase (July 2010 to February 2011). The thirtyday readmission rates were again calculated for each group
and compared to determine if there was a difference in the
thirty-day readmission rates between OPP users and non-OPP
users.
Statistical Analyses
All data were analyzed using IBM SPSS v. 20.0 for Windows
(Armonk, New York). An a priori level of 0.05 was used for
statistical significance. Descriptive statistics were used to
examine OPP use, thirty-day readmissions (ED and IP), age,
and insurance type (private and Medicaid). Differences in
readmission rates, type of readmission (ED or IP), age (<4
years, 5-11 years, and ≥12 years), and insurance status
(private or Medicaid) between OPP users and non-OPP users,
as well as differences in overall OPP utilization, were analyzed
before and during the intervention phase using a Chi-squared
or Kruskal-Wallis test as appropriate.
Results
Pre-Intervention Retrospective Chart Review
The first phase of the study evaluated 4,903 encounters that
met inclusion criteria, occurring from October 2008 to June
2010. Only 578 of these encounters (11.8%) were OPP users
(see Table 1). OPP users had a lower thirty day readmission
rate than non-OPP users. However, the relationship between
OPP-utilization and readmission rate was not statistically
2
significant (6.2% and 7.5%, respectively; χ = 1.15; p = 0.274)
(Table 2).
Second Retrospective Chart Review
The number of OPP users during the intervention phase was
45.9%, an increase from 11.8% pre-intervention. The
relationship between OPP-utilization and study phase was
http://z.umn.edu/INNOVATIONS
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statistically significant (Table 1; χ = 929.04; p < 0.001). A total
of 1,824 encounters were analyzed using a retrospective
chart review at the end of the intervention, revealing 127
thirty-day readmissions (Table 1). Overall, thirty-day
readmission rates in the study population were similar at preintervention (7.3%) and at the second retrospective chart
review (7.5%). However, there was a statistically significant
relationship between OPP-utilization and 30 day readmission
2
rates (Table 2; χ = 52.49; p < 0.001). OPP users had a lower
readmission rate than non-OPP users in the second
retrospective chart review (2.3% and 10.9%, respectively).
Differences in Readmission by Selected Characteristics
Of patients readmitted within 30 days, there were differences
in type of readmission by OPP utilization (Table 3). There was
a statistically significant relationship between OPP-utilization
2
and admission type during the pre-intervention phase (χ =
20.79; p<0.001) and at the second retrospective chart review
2
(χ = 8.67; p=0.007). OPP users had lower emergency
department and inpatient admission rates than non-OPP
users in the pre-intervention phase. Within 30 day
readmissions, there were no significant relationships
between OPP-utilization and age or insurance type (Table 3).
Differences in age and insurance status according to type of
admission also were analyzed for patients readmitted within
30 days (Table 4). There was a statistically significant
relationship between type of admission and OPP-utilization in
patients less than 4 years old who were readmitted within 30
2
days during the intervention phase (χ =10.58; p=0.007) and
patients ages 5-11 who were readmitted within 30 days
2
during the pre-intervention phase (χ =31.93; p<0.001). There
were lower emergency department readmission rates in
pediatrics less than 4 years old who utilized the OPP
pharmacy during the intervention phase and ages 5-11 who
utilized the OPP pharmacy during the pre-intervention phase.
There were no other significant differences by age.
There also was a statistically significant relationship between
admission type and OPP-utilization in patients with Medicaid
as their primary insurer who were readmitted within 30 days
2
in both the pre-intervention (χ =23.86; p<0.001) and
2
intervention (χ =11.08; p=0.001) phases. Of patients who
were readmitted with Medicaid insurance, there were less
OPP-users than non-OPP users during pre-intervention (7.3%
for OPP users, 92.7% for OPP non-users) and at the second
retrospective chart review (11.4% for OPP users, 88.6% for
OPP non-users). There were no other statistically significant
differences by insurance type.
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Discussion
Results from the second retrospective chart review indicated
that the Don’t Leave Without Them program significantly
increased OPP utilization rates, and children who were
discharged from an ED or IP visit for an asthma exacerbation
and picked up discharge medications from the OPP were
significantly less likely to be readmitted within thirty days. In
the pre-intervention chart review, there were no statistically
significant differences between OPP users and non-OPP users
with regard to readmission rates. However, non-OPP users
did have higher readmission rates.
The difference between readmission rates from the preintervention chart review to the second retrospective chart
review was likely due to the significant increase in the
percent of these patients utilizing the OPP, not a change in
practice. The efforts of the pharmacists during the
intervention were mainly focused on communication,
education, and marketing. The actual practices of the
pharmacy did not change during the intervention, but more
patients were receiving the benefits that the pharmacy
offers. By increasing the utilization of the OPP, there were
enough OPP users to detect differences. Post-hoc power
analyses indicated the pre-intervention retrospective chart
review did not provide sufficient power to detect statistical
differences, assuming an effect size of 0.1. A sample size of
785 OPP users was needed to detect differences at the 80%
power level, which was achieved through the intervention for
the second retrospective chart review (N=836).
There are many reasons why OPP users may have had a lower
rate of 30-day readmissions. As previously discussed,
pediatric asthmatics may be at increased risk to encounter
barriers to obtaining the prescription medications they need
1,10-13
to prevent exacerbations.
Patients who utilize the OPP
are able to avoid several of these barriers. The OPP is easily
accessible to those already on the hospital campus, and is
open into the evenings and during the day on weekends to
accommodate patients discharged at those times. The OPP
offers a billing service which ensures that patients are able to
take their medications home that day without any delays due
to gaps in insurance coverage or ability to pay. The patients
who utilize this service may not have been able to get their
medications in a timely manner or at all at another pharmacy.
The OPP also counsels every family when they pick up their
medications. Counseling by a pharmacist can make a great
impact in asthma due to complex inhaler administration
techniques and confusion over the purpose of each
19-24
medication.
Although other community pharmacists are
capable of providing this teaching, they may not act on their
intent to provide asthma counseling to pediatric patients due
to barriers (e.g. lack of time, lack of parent interest, no
http://z.umn.edu/INNOVATIONS
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placebo devices). The OPP pharmacists and interns are
trained to work in pediatric medicine and have access to the
patient’s EMR and are able to easily contact providers to
make necessary recommendations. They also have access to
medical interpreters to serve the institution’s diverse patient
base. Overall, the continuity of care provided by the OPP
likely decreases barriers to obtaining first-fill medications and
increases medication adherence, thereby resulting in lower
readmission rates.
The results of this study may be especially relevant due to the
location of the hospital and the population it serves. As
addressed previously, children with asthma who are ethnic
minorities, from low-income households, inner-city residents,
or who are exposed to tobacco smoke or air pollution are at
1,4,7
higher risk for morbidity and mortality.
The hospital is
located in the inner-city and over 20% of the OPP’s patients
are from the zip codes surrounding the hospital. In 2008, an
average of 47% of the households in these five zip codes had
26
an income < $25,000. Of note, over 50% of patients who
utilize the OPP have state Medicaid insurance. Also, patients
in the study had at least one asthma exacerbation, which
meant they were at risk for future exacerbations and hospital
7,8
readmissions. Any change in practice, such as the
intervention proposed in this study, that could decrease
readmissions in high-risk populations would be beneficial and
should be further investigated.
The results from the secondary objectives identified a few
sub-groups of the population that should be focused on due
to their higher than expected rates of readmission. First, ED
patients who were non-OPP users had higher rates of
readmission in both phases. Since Don’t Leave Without Them
focused heavily on inpatients, the higher rates of readmission
in ED patients were not unexpected. Lower rates of OPP use
in ED patients may also be attributed to the hours of
operation of the OPP, which is not open during the overnight
hours. It is very possible that since ED visits are patient/family
directed as opposed to physician directed, there is a need for
asthma management education in this population. Looking at
non-OPP ED patients by age we see that children ≤ 4 years old
had significantly higher readmissions than their counterparts
who were OPP users. This shows that there is a great
potential to prevent readmissions in this patient population if
they use the OPP. Non-OPP ED patients aged 5-11 years had
higher than expected readmissions in the first phase but not
the second, which shows that readmissions in this age group
may not be as dependent on OPP use as the younger
population. Another group that had higher than expected
readmission rates in both phases was ED, non-OPP users with
Medicaid. Future research should focus interventions
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specifically aimed towards ED patients, specifically those ≤ 4
years old and those with Medicaid as the primary payer.

efforts to decrease readmissions: ED patients; ED patients ≤ 4
years old; and ED patients with Medicaid.

There were several limitations to this analysis. Picking up
prescriptions at the OPP was used as a measure of adherence
to medication, but there are many other factors which could
affect adherence, such as: medication availability and
acquisition from other sources (i.e., home supply, another
pharmacy), lack of proper inhaler technique, and patients
who pick up medication but do not use it. Readmissions to
urgent care centers or other institutions were not
investigated. Furthermore, the clinical appropriateness of
discharge therapy was not assessed, although it is monitored
closely by the OPP pharmacists upon dispensing.

The results should not be applied to readmissions beyond
thirty days, as this is the usual day supply of medication
dispensed, and there is no reason to believe that the benefit
of utilizing an on-campus pharmacy would extend beyond the
supply of the medication. These results apply specifically to
pediatric tertiary care centers with outpatient pharmacies,
but future research is needed to determine the impact of
similar programs at other institutions that provide acute care
to individuals requiring medication therapy to prevent
chronic illness exacerbations. While the study was not
designed to determine a causal relationship between OPP use
and thirty-day readmission rates, it provides evidence that
promoting the use of the OPP for transitional care should
continue to be part of future efforts to decrease
readmissions, and can serve as a model for other institutions.
While the official initiative at this hospital ended in March
2011, the efforts have been on-going due to the success of
the program.

Conclusion
In conclusion, this study found that providing discharge
medications from a pediatric hospital’s outpatient pharmacy
to children with asthma exacerbations may be linked with
decreased rates of readmission within thirty-days. This could
be attributed to increased adherence to medication therapy
and the continuity of care facilitated by the OPP. In addition,
several groups were identified as target groups for future
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Table 1. Differences in Utilization of Outpatient Pharmacy Services (OPP) by Intervention Phase

OPP Users

Pre-Intervention Phase
N=4903
N (%)
578 (11.8)

Intervention Phase
N=1821
N (%)
836 (45.9)

4325 (88.2)

987 (54.1)

Non-OPP Users

Pearson ChiSquare

Significance

929.04

p < 0.001

Table 2. Differences in 30-Day Readmission Rates by Outpatient Pharmacy Service (OPP) Utilization

Pre-Intervention Phase
30-Day Readmission
Yes
N (%)
OPP
Users
Non-OPP
Users

No
N (%)

36 (6.2)

542 (93.8)

324 (7.5)

4001 (92.5)

http://z.umn.edu/INNOVATIONS

Pearson
ChiSquare

1.20

Intervention Phase
30-Day Readmission

Significance

0.274

2012, Vol. 3, No. 4

Yes
N (%)

No
N (%)

19 (2.3)

817 (97.7)

108 (10.9)

879 (89.1)

Pearson
Chi-Square

Significance

52.49

< 0.001
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Table 3. Differences in 30-Day Readmissions by Selected Characteristics and Outpatient Pharmacy Service (OPP) Utilization
Pre-Intervention Phase
Patients Readmitted within 30 Days
OPP User Non-OPP
Pearson
Significance
N (%)
N (%)
Chi-Square
Admission Type
Emergency
Department

20 (6.7)

278
(93.3)

Inpatient

16 (25.8)

46 (74.2)

20.79

KruskalWallis Test

Age
≤4 years

15 (12.4)

106
(87.6)

5-11 years

15 (10.2)

≥12 years

6 (7.3)

132
(89.8)
76 (92.7)

Insurance Type
Private
Medicaid

4 (4.8)
31 (12.2)

http://z.umn.edu/INNOVATIONS

79 (95.2)
224
(87.8)

1.34

Intervention Phase
Patients Readmitted within 30 Days
OPP User Non-OPP
Pearson
Significance
N (%)
N (%)
Chi-Square
11 (10.6)

93 (89.4)

8 (34.8)

15 (65.2)

< 0.001

Significance

0.247

Pearson
Chi-Square

Significance

3.63

0.057
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7 (15.9)

37 (84.1)

6 (12.2)

43 (87.8)

6 (17.6)

28 (82.4)

2 (7.7)
17 (17.5)

24 (92.3)
80 (82.5)

8.67

0.007

KruskalWallis Test

Significance

0.02

0.894

Pearson
Chi-Square

Significance

1.518

0.218
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Table 4. Differences in 30-Day Readmissions by Age, Primary Payer and Outpatient Pharmacy Service (OPP) Utilization

Age

≤4 years

5-11
years

Pre-Intervention Phase
Patients Readmitted within 30 Days
OPP
Non-OPP Pearson
Significance
User
N (%)
ChiN (%)
Square
12
97 (89.0)
1.65
0.199
(11.0)
3 (25.0)
9 (75.0)
4 (3.4)
115
31.93
<0.001
(96.6)

Intervention Phase
Patients Readmitted within 30 Days
OPP
Non-OPP Pearson
Significance
User
N (%)
ChiN (%)
Square
3 (10.5)
34 (91.9)
10.58
0.007
4 (57.1)
4 (10.3)

3 (42.9)
35 (89.7)

11
(39.3)
4 (6.7)

17 (60.7)

2 (20.0)

8 (80.0)

4 (14.3)

24 (85.7)

2 (9.1)

20 (90.9)

2 (33.3)

4 (66.7)

Emergency
Department
Inpatient

4 (5.7)

66 (94.3)

2 (9.1)

20 (90.9)

0 (0.0)

0 (0.0)

4 (100.0)

Emergency
Department
Inpatient

15 (7.3)

13
(100.0)
191
(92.7)
33 (67.3)

9 (11.4)

70 (88.6)

8 (44.4)

10 (56.4)

Type of
Admission
Emergency
Department
Inpatient
Emergency
Department
Inpatient

≥12 years

Primary
Payer
Private

Medicaid

Emergency
Department
Inpatient

http://z.umn.edu/INNOVATIONS

16
(32.7)

56 (93.3)

0.14

0.78

23.86

2012, Vol. 3, No. 4

0.709

0.377

<0.001

0.70

0.402

1.23

0.267

0.394

0.530

11.08

0.001
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Figure 1

Figure 2
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